We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+18.68%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$6.69B
AUM Growth
+$682M
Cap. Flow
-$395M
Cap. Flow %
-5.9%
Top 10 Hldgs %
54.02%
Holding
678
New
246
Increased
85
Reduced
72
Closed
235

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$85.8M
2
INDV icon
Indivior Pharmaceuticals
INDV
+$59.6M
3
BCAX
Bicara Therapeutics
BCAX
+$45.8M
4
MRUS
Merus
MRUS
+$34.4M
5
VTRS icon
Viatris
VTRS
+$30M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$102M
2
SGRY icon
Surgery Partners
SGRY
+$86.4M
3
CPRX
Catalyst Pharmaceutical
CPRX
+$53.7M
4
IART icon
Integra LifeSciences
IART
+$42.8M
5
BNTX icon
BioNTech
BNTX
+$38.6M

Sector Composition

Rank Sector Weight
1 Healthcare 87.45%
2 Industrials 0.73%
3 Technology 0.55%
4 Financials 0.45%
5 Consumer Discretionary 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRSK icon
651
Verisk Analytics
VRSK
$28.2B
– –
-4,151
Closed -$1.12M
VRTX icon
652
Vertex Pharmaceuticals
VRTX
$124B
– –
-1,276
Closed -$598K
VYX icon
653
NCR Voyix
VYX
$1.19B
– –
-107,398
Closed -$1.33M
WAT icon
654
Waters Corp
WAT
$37.3B
– –
-2,139
Closed -$621K
WCN
655
Waste Connections
WCN
$43.5B
– –
-1,603
Closed -$281K
WHR icon
656
Whirlpool
WHR
$2.47B
– –
-4,233
Closed -$433K
WMT icon
657
Walmart Inc
WMT
$908B
– –
-10,384
Closed -$703K
WST icon
658
West Pharmaceutical
WST
$23.7B
– –
-1,409
Closed -$464K
XMTR icon
659
Xometry
XMTR
$4.52B
– –
-17,543
Closed -$203K
XRAY icon
660
Dentsply Sirona
XRAY
$2.86B
– –
-48,972
Closed -$1.22M
YELP icon
661
Yelp
YELP
$1.54B
– –
-33,062
Closed -$1.22M
ZBRA icon
662
Zebra Technologies
ZBRA
$13.6B
– –
-4,147
Closed -$1.28M
GUTS icon
663
Fractyl Health
GUTS
$112M
– –
-834,254
Closed -$3.56M
LENZ
664
LENZ Therapeutics
LENZ
$177M
– –
-17,353
Closed -$300K
JBTM
665
JBT Marel
JBTM
$7.29B
– –
-4,502
Closed -$428K
PDCO
666
DELISTED
Patterson Companies, Inc.
PDCO
– –
-39,244
Closed -$947K
ALTR
667
DELISTED
Altair Engineering Inc
ALTR
– –
-2,113
Closed -$207K
CDMO
668
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
– –
-176,586
Closed -$1.26M
SMAR
669
DELISTED
Smartsheet Inc.
SMAR
– –
-4,640
Closed -$205K
RCM
670
DELISTED
R1 RCM Inc. Common Stock
RCM
– –
-15,338
Closed -$193K
NWLI
671
DELISTED
National Western Life Group, Inc. Class A
NWLI
– –
-408
Closed -$203K
VSTO
672
DELISTED
Vista Outdoor Inc.
VSTO
– –
-6,967
Closed -$262K
23 24 25 26
27

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q3 2024 Portfolio in Review

As of Q3 2024, Deerfield Management held 678 positions worth $6.69B, up 11% from $6.01B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Deerfield Management withdrew a net $395M in Q3 2024, closing 235 positions and reducing 72 holdings. Its most notable exit was Gilead Sciences, an estimated $102M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 83% a quarter earlier, followed by Industrials and Technology.

Against the trend, Deerfield Management opened a new position in Indivior Pharmaceuticals worth $49.7M.

  • Deerfield Management's largest Q3 2024 buy was Indivior Pharmaceuticals: 5,092,642 shares worth $49.7M.
  • Deerfield Management added most to Neurocrine Biosciences in Q3 2024, an estimated $85.8M increase.
  • Deerfield Management's biggest Q3 2024 reduction was Surgery Partners, cutting an estimated $86.4M.
  • Deerfield Management fully exited Gilead Sciences in Q3 2024, selling an estimated $102M.
  • Deerfield Management's ten largest holdings make up 54% of its $6.69B portfolio in Q3 2024.
  • Deerfield Management opened 246 new positions and closed 235 in Q3 2024.
  • Deerfield Management's portfolio value rose 11% quarter-over-quarter to $6.69B.

Based on Deerfield Management's 13F filing for Q3 2024, filed 14 Nov 2024.